Login to Your Account


Nanology LLC's strategy is "almost like having a new molecular entity, in terms of the broadness of the [IP] around it, but on a more streamlined path to potential approval" if safety and efficacy pan out, Marc Iacobucci noted. 

DUBLIN – Proqr Therapeutics NV has spun out a startup firm, Amylon Therapeutics NV, to take forward an RNA-based drug development program focused on rare beta-amyloid-related disorders.

LONDON – Amal Therapeutics SA announced the first closing of its series B funding, raising €8 million (US$9.5 million) of a proposed €20 million round to progress its lead cancer vaccine, ATP-128, into the clinic.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: